1. Home
  2. NTRA vs BEKE Comparison

NTRA vs BEKE Comparison

Compare NTRA & BEKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTRA
  • BEKE
  • Stock Information
  • Founded
  • NTRA 2003
  • BEKE 2001
  • Country
  • NTRA United States
  • BEKE China
  • Employees
  • NTRA N/A
  • BEKE N/A
  • Industry
  • NTRA Medical Specialities
  • BEKE Real Estate
  • Sector
  • NTRA Health Care
  • BEKE Finance
  • Exchange
  • NTRA Nasdaq
  • BEKE Nasdaq
  • Market Cap
  • NTRA 22.1B
  • BEKE 24.7B
  • IPO Year
  • NTRA 2015
  • BEKE 2020
  • Fundamental
  • Price
  • NTRA $167.46
  • BEKE $16.90
  • Analyst Decision
  • NTRA Strong Buy
  • BEKE Strong Buy
  • Analyst Count
  • NTRA 16
  • BEKE 4
  • Target Price
  • NTRA $160.63
  • BEKE $25.97
  • AVG Volume (30 Days)
  • NTRA 1.2M
  • BEKE 5.6M
  • Earning Date
  • NTRA 02-26-2025
  • BEKE 03-13-2025
  • Dividend Yield
  • NTRA N/A
  • BEKE 2.06%
  • EPS Growth
  • NTRA N/A
  • BEKE N/A
  • EPS
  • NTRA N/A
  • BEKE 0.50
  • Revenue
  • NTRA $1,531,955,000.00
  • BEKE $11,766,571,657.00
  • Revenue This Year
  • NTRA $54.35
  • BEKE $18.11
  • Revenue Next Year
  • NTRA $10.17
  • BEKE $11.18
  • P/E Ratio
  • NTRA N/A
  • BEKE $33.96
  • Revenue Growth
  • NTRA 54.94
  • BEKE 11.06
  • 52 Week Low
  • NTRA $62.96
  • BEKE $12.44
  • 52 Week High
  • NTRA $183.00
  • BEKE $26.05
  • Technical
  • Relative Strength Index (RSI)
  • NTRA 52.44
  • BEKE 37.12
  • Support Level
  • NTRA $163.42
  • BEKE $16.35
  • Resistance Level
  • NTRA $174.15
  • BEKE $17.08
  • Average True Range (ATR)
  • NTRA 8.16
  • BEKE 0.60
  • MACD
  • NTRA -0.75
  • BEKE 0.00
  • Stochastic Oscillator
  • NTRA 44.26
  • BEKE 31.19

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

About BEKE KE Holdings Inc (each representing three)

KE Holdings, or Beike, is a large residential real estate sales and rental brokerage company in China. Founded in 2001, the company operates through self-owned Lianjia stores in Beijing and Shanghai and connected third-party agencies including franchise brand Deyou in other cities, with commissions charged on existing-home and new-home transactions. Leveraging an online-offline hybrid model, Beike also attract clients through its namesake online marketplace. The company tapped into home renovation services by acquiring Shengdu Home Decoration in 2022. As of the end of 2023, Beike's cofounders collectively control the company, while Tencent and its affiliates share 8% of voting power.

Share on Social Networks: